title: Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors.
authors.forename: Y
authors.initials: Y
authors.lastname: Minami
authors.forename: A
authors.initials: A
authors.lastname: Abe
authors.forename: M
authors.initials: M
authors.lastname: Minami
authors.forename: K
authors.initials: K
authors.lastname: Kitamura
authors.forename: J
authors.initials: J
authors.lastname: Hiraga
authors.forename: S
authors.initials: S
authors.lastname: Mizuno
authors.forename: K
authors.initials: K
authors.lastname: Ymamoto
authors.forename: M
authors.initials: M
authors.lastname: Sawa
authors.forename: Y
authors.initials: Y
authors.lastname: Inagaki
authors.forename: K
authors.initials: K
authors.lastname: Miyamura
authors.forename: T
authors.initials: T
authors.lastname: Naoe
mesh_terms: D000359:Aftercare; D018952:Antigens, CD34 / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018365:Neoplasm, Residual / Q000188:drug therapy* / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000473:pathology*; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl